Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04962958 | Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | completed | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05171387 | Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer | completed | Phase 2 | 78 | BayerINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07040956 | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. | completed | Phase 2 | 98 | West China HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07671495 | Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin(ATSMAIN) | completed | Phase 2 | 278 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT07671547 | Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy(NADERIN-BC) | completed | Phase 2 / Phase 3 | 79 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT00165256 | Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast | completed | Phase 2 | 157 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 454 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 336 | Forma Therapeutics, Inc.INDUSTRY | 9 | Jun 29, 2026 | clinicaltrials |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma(PRIME-HCC) | completed | Phase 1 / Phase 2 | 33 | Imperial College LondonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04195945 | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04975698 | HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903(BMTCTN1903) | completed | Phase 2 | 12 | Catherine BollardNIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05359861 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 30 | Coherus Oncology, Inc.INDUSTRY | 4 | Jun 29, 2026 | clinicaltrials |
| NCT00209989 | Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme | completed | Phase 2 | 27 | Institut Claudius RegaudOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01750073 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | completed | Phase 2 | 92 | University of NebraskaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03323346 | Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer(DISC) | completed | Phase 2 | 9 | The Institute of Molecular and Translational Medicine, Czech RepublicOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 2 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma(PrE0404) | completed | Phase 1 / Phase 2 | 43 | PrECOG, LLC.OTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668076 | The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients | completed | Phase 2 | 44 | Damanhour UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00887159 | A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage | completed | Phase 2 | 168 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT01642251 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT01657331 | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)(SGN+Benda) | completed | Phase 1 / Phase 2 | 65 | Columbia UniversityOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT04528394 | Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma | completed | Phase 2 | 136 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04703322 | A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan | completed | Phase 2 | 9 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05412446 | 99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes(99mTc-ADAPT6) | completed | Phase 2 | 30 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06884670 | Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study | completed | Phase 2 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT01415882 | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | completed | Phase 2 | 165 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04084717 | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04318938 | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | completed | Phase 2 | 118 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04919512 | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder(SunRISe-4) | completed | Phase 2 | 163 | Janssen Research & Development, LLCINDUSTRY | 10 | Jun 23, 2026 | clinicaltrials |
| NCT05742750 | A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer(HP-BTC-001) | completed | Phase 1 / Phase 2 | 49 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03294083 | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | SillaJen, Inc.INDUSTRY | 3 | Jun 18, 2026 | clinicaltrials |
| NCT03508726 | High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas | completed | Phase 1 / Phase 2 | 25 | Mohammed MilhemOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04457284 | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04552990 | Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 468 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05721443 | Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC | completed | Phase 2 | 28 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01242930 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | completed | Phase 2 | 13 | Geron CorporationINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01821729 | Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer | completed | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT03213041 | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer | completed | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 30, 2026source: clinicaltrials